IQV241220C240000
- 0.40
- 0.000.00%
IQVIA Holdings Newsroom
Goldman Sachs Adjusts Price Target on IQVIA Holdings to $230 From $250, Maintains Buy Rating
Baird Maintains IQVIA Holdings(IQV.US) With Hold Rating, Cuts Target Price to $213
Baird Adjusts Price Target on IQVIA Holdings to $213 From $223, Maintains Neutral Rating
Deutsche Bank Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $265
IQVIA Hldgs Analyst Ratings
Mizuho Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $247
Argus Research Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $260
Argus Cuts Price Target on IQVIA to $260 From $280
RBC Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $270
IQVIA Holdings Price Target Maintained With a $270.00/Share by RBC Capital
JP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $240
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $240 to $273
Analysts Offer Insights on Healthcare Companies: Glaukos (GKOS), Regeneron (REGN) and IQVIA Holdings (IQV)
Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)
Stifel Nicolaus Reaffirms Their Buy Rating on IQVIA Holdings (IQV)
IQVIA Hldgs Analyst Ratings
Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $265
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $235 to $265
IQVIA Holdings Price Target Cut to $250.00/Share From $280.00 by Goldman Sachs
IQVIA Holdings Is Maintained at Buy by Goldman Sachs